ABOUT US

Dr Timothy Schulz-Utermoehl

BSc MSc PhD

Discover

OUR BACKGROUND

Timothy Schulz-Utermoehl has over 20 years of DMPK experience within the academic, pharmaceutical, biotech and CRO sector, spanning early- and late- stage discovery research as well as preclinical development.

Timothy started his career in the pharmaceutical industry as a post-doctoral research fellow within the DMPK group at Novo Nordisk in Denmark.

He subsequently moved to Merck Sharp & Dohme to work at their Neuroscience Research Centre in the UK within the Lead Optimisation phase of Discovery DMPK in support of CNS discovery projects.

Timothy then moved to AstraZeneca's Alderley Park site to work  within Development DMPK in support of their Oncology and Infection Therapy area, where he held  various roles of increasing responsibility, including  ADME Section  Head within the Oncology iMED DMPK department.

He then joined Shire Pharmaceuticals as a DMPK Director within the Exploratory Projects Group, where he had responsibility for the early discovery projects and was responsible for the outsourcing of DMPK activities in support of GI and CNS projects. He was also a member of the Business Development Haematology opportunities team, participating and providing scientific and technical inpu​t to BD in support of external licensing and partnering opportunities in the haematology area. This included due diligence and M&A discussions.

Timothy then took a role as Director, Head of DMPK, at Sygnature Discovery focused on setting up a full Discovery DMPK capability at Sygnature, the UK's largest independent provider of integrated research projects.

Timothy received his B.Sc. combined honours degree in Pharmacology & Physiology at the University of Leeds and his M.Sc. degree in Toxicology at the Royal Postgraduate Medical School, University of London. He studied for his P.hD. in Biochemistry at Imperial College School of Medicine in London.